Hollencrest Capital Management Viking Therapeutics, Inc. Transaction History
Hollencrest Capital Management
- $2.36 Billion
- Q3 2024
A detailed history of Hollencrest Capital Management transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Hollencrest Capital Management holds 2,459 shares of VKTX stock, worth $116,138. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,459
Previous 2,459
-0.0%
Holding current value
$116,138
Previous $130,000
19.23%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
474Shares Held
66.2MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$480 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$285 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$221 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$100 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$88.5 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.62B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...